IP Library Granted Patent US 7,153,493
Granted Patent B2
US 7,153,493 · App. 10/630,526 · Granted Dec 26, 2006

Clear oral compositions containing potassium salt

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,153,493
App. No.
10/630,526
Granted
Dec 26, 2006
Kind
B2
Abstract

The subject invention provides compositions useful in oral cavity, comprising an effective amount of a soluble potassium salt, a sodium (C 2–C 24 ) alkylsulfate in an amount effective to remove or loosen debris and/or stains from a surface, and a polar surfactant, said surfactant comprising a hydrophobic portion selected from a (C 6 –C 30 ) alkyl group and a polymeric silicone group, wherein the molar ratio of the surfactant to the sodium (C 8 –C 24 ) alkylsulfate is greater than or equal to about 1:1. The subject invention also provides a mint flavoring that does not comprise a substantial amount of menthol, said mint flavoring being either a dementholated natural mint extract or a synthetic blend.

Claims (21)

1. An oral mouthrinse composition for reducing nerve sensitivity comprising:

(a) from about 0.01% by weight to about 5% by weight of an orally-acceptable, soluble potassium salt;

(b) from about 0.01% by weight to about 10% by weight of a sodium (C 8 –C 24 ) alkylsulfate;

(c) from about 0.01% by weight to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a C 6 –C 30 ), fatty acid mono or diester of ethoxylated sorbitan, a (C 6 –C 30 ) fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 –C 30 ) fatty acyl sarcosinate, a (C 6 –C 30 ) fatty acyl ester of sarcosine acid, a sodium salt of a (C 6 –C 30 ) fatty acyl taurate, a sodium salt of a (C 6 –C 30 ) fatty acyl methyltaurate, a (C 6 –C 30 ) fatty acyl ester of taurine, a (C 6 –C 30 ) fatty acyl ester of methyltaurine acid, a (C 6 –C 30 ) fatty acyl betaine, a ( C 6 –C 30 ) fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and

(d) an orally-acceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of (c) to the sodium (C 8 –C 24 ) alkylsulfate is greater than or equal to about 1:1 such that when a.), b.), a.) are dissolved in d.), the resultant composition is clear.

2. The oral mouthrinse composition according to claim 1 , wherein the soluble potassium salt of the composition comprises a potassium pyrophosphate salt in an amount effective, optionally in combination with other pyrophosphate salts, to remove or loosen plaque and/or stains when the composition is orally applied to a dental surface.

3. The oral mouthrinse composition according to claim 1 , wherein the soluble potassium salt of the composition comprises soluble potassium salt that possesses activity in reducing dental nerve and/or dentin sensitivity in an amount effective to reduce dental nerve and/or dentin sensitivity when the composition is orally applied to a dental surface.

4. The oral mouthrinse composition according to claim 3 , wherein the soluble potassium salt that possesses activity in reducing dental nerve and/or dentin sensitivity is potassium nitrate.

5. The oral mouthrinse composition according to claim 3 , further comprising a flavoring that does not comprise a substantial amount of menthol.

6. The oral mouthrinse composition according to claim 5 wherein the flavoring that does not comprise a substantial amount of menthol is a mint flavoring.

7. The oral monthrinse composition according to claim 1 , wherein the soluble potassium salt is selected from the group consisting of a potassium pyrophosphate salt, potassium nitrate, and mixtures thereof.

8. An oral composition in the form of a rinse for reducing dental nerve and/or dentin sensitivity comprising

(a) from about 0.1% to about 5% potassium nitrate;

(b) from about 0.02% to about 2% SLS;

(c) from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a (C 6 –C 30 ) fatty acid mono diester of ethoxylated sorbitan, a (C 6 –C 30 ) fatty acid diester of polyethylene glycol, a sodium salt of a (C 6–C 30 ) fatty acyl sarcosinate, a (C 6 –C 30 ) fatty acyl ester of sarcosine acid, a sodium salt of a (C 6 –C 30 ) fatty acyl taurate, a sodium salt of a (C 6 –C 30 ) fatty acyl methyltaurate, a (C 6 –C 30 ) fatty acyl ester of taurine, a (C 6 –C 30 ) fatty acyl ester of methyltaurine acid, a (C 6 –C 30 ) fatty acyl betaine, a (C 6 –C 30 ) fatty quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phosphate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane, copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and

(d) an orally-acceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of (c) to the sodium (C 8 –C 24 ) alkylsulfate is greater than or equal to about 1:1 such that when a.), b.), c.) are dissolved in d.), the resultant composition is clear.

9. An oral composition in the form of a rinse for removing or loosening plaque and/or stains from dental surfaces comprising

(a) from about 0.1% to about 5% of a potassium salt selected from the group consisting of dipotassium pyrophosphate, tetrapotassium pyrophosphate, tripotassium pyrophosphate, monopotassium pyrophosphate, and combinations thereof;

(b) from about 0.02% to about 2% SLS;

(c) from about 0.1% to about 20% by weight of an orally-acceptable polar surfactant, said surfactant selected from the group consisting of a (C 6 –C 30 ) fatty acid mono or diester of ethoxylate sorbitan, a (C 6 –C 30 ) fatty acid diester of polyethylene glycol, a sodium salt of a (C 6 –C 30 ) fatty acyl sarcosinate, a (C 6 –C 30 ) fatty acyl ester of sarcosine acid, a sodium salt of a (C 6 –C 30 ) fatty acyl taurate, a sodium salt of a (C 6 –C 30 ) fatty acyl methyltaurate, a (C 6 –C 30 ) fatty acyl ester of taurine, a (C 6 –C 30 ) fatty acyl ester of methyltaurine acid, a (C 6 –C 30 ) fatty acyl betaine, a (C 6 –C 30 ) fatty acyl quaternary ammonium chloride, dimethicone copolyols, polydimethylsiloxane phosphate esters, polydimethylsiloxane copolyol phospohate esters, polydimethylsiloxane phosphobetaines, polydimethylsiloxane copolyol phosphobetaines, polydimethylsiloxane taurates, polydimethylsiloxane copolyol taurates, acetylated polydimethylsiloxane copolyols, and polydimethylsiloxane quaternium compounds, polydimethylsiloxane copolyol quaternium compounds; and

(d) an orally-acceptable aqueous vehicle comprising from about 50% to about 85% water; wherein the potassium salt is dissolved in the composition and wherein the molar ratio of the surfactant of (c) to the sodium (C 8 –C 24 ) alkylsulfate is greater than or equal to about 1:1 such that when a.), b.), c.) are dissolved in d.), the resultant composition is clear.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 1, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036042/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2007
From: PFIZER INC; PFIZER PRODUCTS INC; PFIZER JAPAN INC; G.D. SEARLE LLC; PHARMACIA CORPORATION; PHARMACIA & UPJOHN COMPANY LLC; WARNER LAMBERT COMPANY LLC
To: MCNEIL-PPC, INC
Reel/Frame 019573/0631 →